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Introduction: Doege-Potter syndrome is a paraneoplastic syndrome characterized by non-islet cell tumor
hypoglycemia secondary to a solitary fibrous tumor. This tumor causes hypoglycemia by the secretion of a prohormone
form of insulin-like growth factor II. We describe the diagnosis and management of Doege-Potter syndrome and the
use of transarterial chemoembolization in a patient with a malignant extrapleural solitary fibrous tumor.
Case presentation: Our patient was a 64-year-old Caucasian woman who initially presented with urinary incontinence
and was found to have a 14.5×9.0×9.0cm retroperitoneal solitary fibrous tumor compressing her bladder. Her tumor
was surgically resected but recurred with multiple hepatic metastatic lesions. The hepatic metastases progressed
despite systemic chemotherapy and treatment with doxorubicin transarterial chemoembolization. Her course was
complicated by the development of recurrent fasting hypoglycemia, most likely secondary to Doege-Potter syndrome.
Her hypoglycemia was managed with corticosteroid therapy and frequent scheduled nutrient intake overnight.
Conclusions: The rarity of hepatic solitary fibrous tumors and consequent lack of controlled trials make this report
significant in that it describes the diagnostic approach to Doege-Potter syndrome, describes our experience with the
use of doxorubicin transarterial chemoembolization, and presents management options for tumor-associated
hypoglycemia in the case of extensive disease not amenable to surgical resection.Introduction
Doege-Potter syndrome [1,2] is a paraneoplastic syndrome
characterized by non-islet cell tumor hypoglycemia
(NICTH) secondary to a solitary fibrous tumor (SFT) that
secretes a prohormone form of insulin-like growth factor
II (IGF-II). Doege-Potter syndrome is an uncommon com-
plication of an uncommon tumor. However, it is poten-
tially life-threatening, and thus requires a careful and
attentive approach to diagnosis and management. The fol-
lowing describes the diagnosis and management of Doege-
Potter syndrome in a patient with an extrapleural solitary
fibrous tumor (ESFT) complicated by hepatic metastases.* Correspondence: rob.schutt@virginia.edu
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reproduction in any medium, provided the orCase presentation
Our patient is a 64-year-old Caucasian woman who ini-
tially presented with urinary incontinence. She was found
to have a 14.5×9.0×9.0cm retroperitoneal pelvic mass
compressing her bladder. She did not have symptoms of
hypoglycemia at this time. Our patient subsequently
underwent exploratory laparotomy with resection of the
retroperitoneal mass, sigmoidectomy and colostomy. On
gross examination, the 14.5cm retroperitoneal mass was
well-encapsulated with only central focal areas of necrosis.
On microscopic examination, the tumor demonstrated
increased cellularity, mildly pleomorphic epithelioid cells
and 15 mitotic figures per 10 high power fields. Atypical
mitotic figures were not appreciated. By contrast, the liver
metastases were partially necrotic, and were composed of
moderately pleomorphic sarcomatoid cells with far more
numerous mitotic figures. Immunohistochemical stainingLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ferentiation (CD)-34 and B-cell lymphoma-2, with patchy
positivity for vimentin. The tumor cells were negative for
CD-99, estrogen receptor protein, CD-10, CD-117,
muscle-specific actin, desmin, smooth muscle actin, epithe-
lial membrane antigen, CD-31, keratin, S-100, inhibin and
CD-56. The diagnosis of ESFT was made based on the
microscopic and immunohistochemical findings. Selected
images from the pathological evaluation are presented in
Figure 1.
Our patient was followed-up with serial imaging, first at
three months after resection, then at 15 months post-
resection. On the latter scan, four new hepatic masses were
identified: an 8.3×10.4cm mass within hepatic segment
two, a 4.4×4.8cm mass within hepatic segment four, a
6.8×5.5cm lesion within hepatic segment eight, and a
2.2×2.2cm lesion within hepatic segment six. Fine needle
aspiration of the largest lesion demonstrated a similar
immunohistochemical profile to the primary retroperito-
neal ESFT, and the newly identified masses were consid-
ered metastatic malignant ESFT. At this time, she was
started on the multi-targeted receptor tyrosine kinase in-
hibitor sunitinib for treatment of the hepatic metastases.(A)
(C)
Figure 1 Selected images from the pathological evaluation. (A) The re
vascular pattern. Mitotic figures are frequent, but no atypical forms are seen (h
CD34 performed on the retroperitoneal mass (10×). (C) A core biopsy of the l
areas of necrosis (hematoxylin and eosin stain 10×). (D) An immunohistochemHowever, this was discontinued three months later due to
the development of erythema multiforme, hyponatremia
and thrombocytopenia. Given this sunitinib intolerance,
she was treated with temozolomide and intravenous beva-
cizumab for four months. This regimen was tolerated well,
but subsequent imaging demonstrated progression of the
disease. The liver lesions were then treated with transarte-
rial chemoembolization (TACE) using doxorubicin beads
on two separate occasions - at 22 months and 24 months
after initial diagnosis and resection. Despite chemoemboli-
zation, the liver lesions continued to progress in size, and a
new lesion developed.
Approximately 22 months after her initial diagnosis
(prior to the first TACE procedure) our patient developed
symptomatic hypoglycemia. Her initial episode was her-
alded by a period of disorientation lasting approximately
one hour. Her blood glucose was documented to be
41mg/dL at this time. These symptoms progressed to fre-
quent overnight hypoglycemia requiring frequent snacking
to maintain a normal blood glucose level. During the
second chemoembolization procedure, she had persistent
hypoglycemia (less than 40mg/dL), likely related to pre-
procedural fasting. Reversal of hypoglycemia during the(B)
(D)
troperitoneal mass is composed of cellular fusiform cells with a staghorn
ematoxylin and eosin stain 10×). (B) An immunohistochemical stain for
iver shows increased cellularity and increased cellular pleomorphism, with
ical stain for CD34 performed on liver mass (10×).
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50% dextrose. Our patient was subsequently admitted to
the hospital for evaluation of her hypoglycemia. During
hospitalization, her blood glucose level decreased precipi-
tously multiple times. Our patient’s hypoglycemia oc-
curred primarily with fasting and was ameliorated with
continuous dextrose 10% infusion and frequent snacks
(for example, liquid nutritional supplements).
A laboratory evaluation was performed while our pa-
tient was hypoglycemic (blood glucose 26mg/dL), and
pertinent results are listed in Table 1. Notably, she had
low insulin and C-peptide concentrations in the setting
of hypoglycemia, which effectively excluded insulinoma,
ectopic insulin production or exogenous insulin admin-
istration as the cause of hypoglycemia. IGF-II and IGF-I
was measured, and the IGF-II:IGF-I ratio was elevated at
9.60 (3:1 is normal, and >10 has been suggested to be
pathognomonic for NICTH) [3]. In addition, a large
sized tumor (>10cm) in the setting of hypoinsulinemic
hypoglycemia indicated NICTH as the etiology for her
hypoglycemia [4]. Thus, paraneoplastic Doege–Potter
syndrome [5] was considered the most likely etiology of
this patient’s hypoglycemia.
Extensive damage (replacement) of liver parenchyma
with reduced hepatic glucose production was consid-
ered, as our patient had significant hepatic metastases.
One milligram of glucagon was administered when her
venous blood glucose level was 26mg/dL; 30 minutes
after glucagon administration, her blood glucose had
only risen to 54mg/dL (increment of 28mg/dL). LimitedTable 1 Laboratory evaluation for hypoglycemia
Test Result Reference range
Glucose 26mg/dL 74 to 99mg/dL
Insulin <2.0μIU/mL <20μIU/mL
Proinsulin 2.7pmol/L 3 to 20pmol/L














20pg/mL 9 to 52pg/mL











aMolar concentrations were calculated based on conversion factor of 0.131 for
IGF-I and 0.133 for IGF-II.data suggest that an increment of less than or greater
than 30mg/dL may distinguish patients with reduced
hepatic glucose production from those with excessive in-
sulin (or insulin-like) action, respectively [6]. Of interest,
it is said that over 80% of the hepatic mass must typically
be destroyed before this alone would cause fasting
hypoglycemia [7], and although there was significant tumor
involvement of the liver, imaging in our patient suggested
that at least 20% normal liver remained (Figure 2). She also
had evidence of normal synthetic function with an inter-
national normalized ratio of 1.2 (reference range 0.9 to
1.2). However, it is certainly possible that concurrent ab-
normalities (for example, malnutrition) in combination
with her hepatic metasteses may have contributed to
reduced hepatic glucose production and this may have
manifested before detection of reduced hepatic synthetic
capacity. With all available data taken together, we felt that
reduced hepatic mass may have contributed to our
patient’s fasting hypoglycemia, but it was unlikely to be the
primary cause.
Hypoglycemia in this patient was most prominent
overnight when her food intake decreased, and she had
life-threatening nocturnal hypoglycemia on a number of
occasions. Therefore, management of Doege-Potter syn-
drome in our patient was focused on maintaining eugly-
cemia overnight. Potential management strategies are
described in Table 2. Treatment options were discussed
at length with our patient, and the decision was made to
pursue non-invasive management strategies first. Initial
management included scheduled, intermittent ingestion
of liquid nutritional supplements overnight, triggered
every three hours by an automatic alarm. Each liquid
nutritional supplement (Ensure PlusW) contained 350
kilocalories, 50g of carbohydrate, 11g of fat and 13g of
protein. In addition, 10mg of oral prednisone was admi-
nistered daily [8]. This regimen appeared to prevent
overnight hypoglycemia in the hospital, and our patient
was discharged on 10mg oral prednisone to be takenFigure 2 Computed tomography scan of the abdomen
demonstrating metastatic solitary fibrous tumor involvement
of the liver.




Most solitary fibrous tumors are benign and adequate
resection resolves hypoglycemia




May be used to treat non-resectable tumors Chemotherapy regimens are not well studied; significant side
effects associated with chemotherapy; tumors are typically
poorly responsive to systemic chemotherapy









Reliably prevents hypoglycemia Long-term use requires invasive placement of gastrostomy tube
Corticosteroid
administration
Non-invasive; may normalize insulin-like growth factor
levels; increases appetite




Effective to prevent hypoglycemia in some patients;
subcutaneous administration has less infectious risk than
direct venous access
May be practically difficult
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to be taken consistently at 10:00 p.m., 1:00 a.m. and 4:00
a.m. On clinic follow-up two weeks later, her appetite
had improved, she had gained three pounds, and she
had well-controlled blood glucose levels all day with fre-
quent snacks. Overnight hypoglycemia was less frequent,
although her blood glucose levels periodically decreased
into the 30s and 40s mg/dL, especially around 1:00 a.m.
and between 5:00 and 7:00 a.m. She had not adhered to
the scheduled liquid nutritional supplements, although
she was eating throughout the night. Her prednisone
regimen was changed to 7.5mg in the morning and
2.5mg in the evening. To help achieve steady blood glu-
cose levels over longer periods of time, we also recom-
mended eating snacks with raw cornstarch, which is
relatively slowly digested by pancreatic amylase [9,10].
Unfortunately, our patient had rapid clinical deterioration
shortly thereafter. Her appetite decreased significantly, she
developed marked ascites, and she was admitted to another
hospital with failure to thrive, atrial fibrillation and hypo-
tension. She was discharged home with hospice care and
passed away two days later. Due to her rapid clinical course,
she was not able to start the raw cornstarch diet, and she
continued to have episodic overnight hypoglycemia until
her death.
Discussion
SFTs are rare spindle cell neoplasms first described cli-
nically in 1870 by Wagner [11] and subsequently
described by histopathology by Klemperer and Rabin in
1931 [12]. SFTs often derive from the pulmonary pleura,
but they may also occur outside the pleura as ESFTs.
ESFTs are rare soft tissues tumors; in one large retro-
spective series involving over 4000 soft tissue tumors
obtained over 18 years, only 79 SFTs were identified, 54of which were intrathoracic in origin [13]. Doege-Potter
syndrome [1,2] is a paraneoplastic condition defined by
NICTH secondary to a SFT; this occurs in less than 5%
of SFT cases [14]. Table 3 presents a list of prior cases of
Doege-Potter syndrome. The typical mechanism of
hypoglycemia with SFTs involves tumor production of a
prohormone form of IGF-II, often called ‘big IGF-II’
[15]. Big IGF-II causes hypoglycemia through multiple
mechanisms [6,16,17]. Insulin-like effects of big IGF-II
lead to increased glucose uptake by insulin-sensitive tis-
sues, especially muscle and fat, but it may also stimulate
glucose uptake by the tumor itself. Decreased hepatic
glucose production may also be related to the insulin-
like effect of big IGF-II, and glucagon secretion may be
low in NICTH as well.
IGF-II assay results are frequently in the normal refer-
ence range in NICTH, and assays for big IGF-II are not
commercially available. However, the IGF-II:IGF-I molar
ratio is considered to be a surrogate marker of big IGF-
II concentration [17]. In NICTH, IGF-II provides central
negative feedback of growth hormone, with a subsequent
reduction of IGF-I production. This contributes to an in-
crease in the IGF-II:IGF-I ratio; a ratio of 3:1 is consid-
ered normal, with a ratio greater than 10 reported to be
virtually pathognomonic for NICTH [3]. Parenthetically,
decreased growth hormone secretion also leads to lower
concentrations of IGF-binding proteins, which may in-
crease the bioavailability of IGF-II [16].
Our case highlights the importance of considering
Doege-Potter syndrome in a patient with SFT and hypo-
glycemia. This is especially important when the tumor is
large (larger than 8cm to 10cm), as this is thought to be a
risk factor for the development of this paraneoplastic syn-
drome [14,36]. In our case, the presence of massive liver
metastases with extensive liver replacement complicated
Table 3 Summary of prior cases of Doege-Potter syndrome
Author Year Case information
Doege [1] 1930 The patient presented with facial flushing and symptoms of irrationality described as ‘maniacal seizures’ noted to
improve with treatment by rectal glucose, morphine and scopolamine. Symptoms continue to recur and urine analysis
demonstrated traces of acetone. The patient was found to have 26×16cm tumor filling nearly the entire left thoracic
cavity, and was treated with surgical excision and noted to be without recurrence at a three-year follow-up.
Potter [2] 1930 The patient was found to be delirious at times and was found to have a large tumor filling the entire left side of the
thoracic cavity. The patient subsequently underwent two-stage surgical resection five days apart and made an
uneventful recovery.
Arkless [18] 1942 The patient had a history of convulsive seizures and was found to have a left subphrenic mass. Removal resolved the
seizures. Seven years later the patient presented with hypoglycemia. This was managed on a high carbohydrate diet
and the patient died. A spindle cell sarcoma of the left chest was found postmortem.
Hines [19] 1943 A patient with recurrent hypoglycemia was found to have a sarcoma of the right upper abdomen.
Skillern et al. [20] 1954 The patient had two large tumors composed of round and spindled cells and was found to have recurrent
hypoglycemia.
Frantz and Porter [21] 1956 The patient presented with recurrent hypoglycemia and was found to have a large pelvic mass encasing the ovary,
thought to be a spindle cell neoplasm.
Holten [22] 1957 A patient with a spindle cell tumor causing hypoglycemia.
Scholz et al. [23] 1957 Two cases of patients who presented with recurrent hypoglycemia. In one patient, surgical resection of the tumor
(described as a renal fibrosarcoma) resolved the hypoglycemia.
August and Hiatt [24] 1958 Patient with frequent episodes of hypoglycemia that ceased with surgical resection of a large intrathoracic
fibrosarcoma.
Grilliat et al. [25] 1970 Tumor described as a pleural mesothelioma associated with hypoglycemia.
Ellorhaoui and Graf
[26]
1976 Patient with an intrathoracic tumor found to have hypoglycemia and diagnosed with Doege-Potter syndrome.
Vollmar and Wockel
[27]




1979 Intrathoracic spindle cell tumor.
Kecskés et al. [29] 1979 Thoracic mesenchymal tumor treated with surgical resection.
Dao et al. [30] 1984 Pleural tumor in a patient with hypoglycemia.
Heinrich et al. [31] 1984 Tumor described as an intrathoracic fibroma.
Lessel and Erbstosser
[32]
1984 Malignant fibrous histocytoma of the right lung that infiltrated the spinal column causing paralysis, no metastatic
disease identified.
Roy et al. [33] 1992 Recurrent SFT of the pleura.
Abonyi et al. [34] 1992 Left-sided pleural mesothelioma and electron microscopy demonstrated neurosecretory granules thought to be
insulin-like growth factor II-like material.
Gullo et al. [8] 1999 Abdominal hemangiopericytoma treated with resection, developed recurrence that was treated with chemotherapy
and radiotherapy, with subcutaneous biosynthetic growth hormone and prednisone to mitigate symptoms.
Chamberlain and
Taggart [5]
2000 Tumor described as a sub-pleural fibroma measuring 23×21×12cm, treated with surgical resection and noted to have
complete recovery.
Herrmann et al. [35] 2000 Malignant fibrous histiocytoma of the lung with tumor size described as 13×8cm.
Zafar et al. [36] 2003 Pleural SFT measuring 19×15×14cm.
Kafih et al. [37] 2005 Pleural fibrous tumor involving entire left hemithorax.
Balduyck et al. [38] 2006 Pleural SFT measuring 22×19×7cm.
Lucas and
Ledgerwood [39]
2006 Malignant SFT of small bowel mesentery, measuring 10×12×20cm.
Hirai[40] 2006 Pleural SFT measuring 10.9×9.8×9.4cm treated with surgical resection, found to have corresponding resolution of
hypoglycemia associated with decrease in serum insulin-like growth factor II level postoperatively.
Milenković et al. [41] 2007 Benign SFT involving almost the entire hemithorax.
Kalebi et al. [42] 2009 Pleural SFT measuring 20×15×10cm, treated with surgical resection.
Lee et al. [43] 2010 Thoracic SFT described pathologically as a low malignant potential tumor.
Fung and Crook [44] 2011 Patient with tumor associated with spontaneous hypoglycemia.
Campos et al. [45] 2012 Pleural SFT measuring 27×25×11.5cm.
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Table 3 Summary of prior cases of Doege-Potter syndrome (Continued)
Rosseel et al. [46] 2012 Patient with hypoglycemia and found to have a right thoracic mass.
Herrak et al. [47] 2012 Doege-Potter syndrome diagnosed in patient with a pleural tumor.
SFT: solitary fibrous tumor.
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markedly reduced hepatic glucose output (for example,
reduced glycogen stores) was considered; for reasons
described previously, this was not felt to be the primary
cause of our patient’s hypoglycemia, although it likely con-
tributed. Liver replacement may also have been respon-
sible for an IGF-II:IGF-I ratio less than 10, as shown in a
case series of patients with NICTH secondary to a com-
bination of liver destruction and excessive secretion of big-
IGF-II, in which the patients had a lower than expected
IGF-II:IGF-I ratio [4].
Treatment options for Doege-Potter syndrome can be
divided into therapies that directly reduce tumor burden
(for example, surgery, chemotherapy) and therapies that
mitigate hypoglycemia without treating the underlying
tumor. Our patient’s hepatic metastases exhibited no
clear response to employed treatments. TACE has been
used for treatment of ESFTs that are not surgically resect-
able, but there are few data regarding TACE for hepatic
ESFT [47]. This in part reflects its rarity; a recent review
summarizing treatment approaches to hepatic ESFT found
only 30 cases of hepatic ESFT [48]. TACE did not appear
to be effective in our patient, as follow-up imaging one
month after the second TACE procedure demonstrated
significant progression of disease. This is in contrast to a
prior case report that demonstrated imaging evidence of
response and a stable tumor size in a patient with a SFT
treated with doxorubicin chemoembolization [49].
For our patient, we focused significant attention on her
hypoglycemia, which was an immediately life-threatening
problem. In this case, any period of fasting for more than
four hours was associated with marked hypoglycemia.
During the day, our patient prevented severe hypo-
glycemia via frequent food intake, but prevention of over-
night hypoglycemia was more problematic. While under
close observation in our hospital, it was clear that conti-
nuous administration of either enteral or parental nutri-
tion was effective at preventing overnight hypoglycemia.
Possible long-term treatment options are outlined in
Table 2. Management options can be significantly different
with regard to efficacy, reliability, invasiveness and risk of
side effects; with the exception of surgical resection, there
are few data to strongly support one modality over an-
other. After thorough discussion of her options, our pa-
tient chose frequent overnight food intake in addition to
corticosteroid therapy (oral prednisone, 10mg daily). Al-
though this improved our patient’s hypoglycemia, she con-
tinued to have periodic hypoglycemia until her death.Conclusions
Doege-Potter syndrome is an uncommon paraneoplastic
phenomenon associated with SFT characterized by hypoin-
sulinemic hypoglycemia. In our case, our patient had a ma-
lignant ESFT that was not amenable to surgical resection
and did not respond to doxorubicin TACE. The diagno-
sis of Doege-Potter syndrome in our patient was based
on the large size of the SFT, low insulin level measured
while hypoglycemic, and elevated IGF-II:IGF-I ratio.
Her hypoglycemia was managed with daily corticoste-
roid therapy and frequent nutrient intake, with frequent
alarm reminders overnight.
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